ArticleInternational journal of cardiology. Heart & vasculature2025
Diagnostic performance and risk assessment of combined copeptin and high-sensitivity cardiac troponin I in Chinese emergency department.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapid and early identification of acute myocardial infarction (AMI) is crucial for initiating timely treatment and assessing post-discharge risks. Copeptin's unique release profile may help detect early myocardial damage, particularly when high-sensitivity cardiac troponin I (hs-cTnI) is undetectable. However, there is a limited understanding of copeptin's application in the Chinese population, highlighting the need for further research. Methods: A prospective cohort study was conducted, enrolling 414 consecutive patients presenting to the emergency department (ED) within 6 h of chest pain onset. Baseline clinical characteristics were recorded, and copeptin and hs-cTnI levels were measured from the initial blood draw. Patients were followed for 180 days to determine the occurrence of major adverse cardiovascular events (MACE). The final diagnosis was independently adjudicated by a panel of cardiologists blinded to copeptin results. Results: Of 414 Chinese patients, 112 (27.05 %) had AMI. In hs-cTnI-undetectable patients, median copeptin was 290 pmol/L (IQR: 211-547) in STEMI and 130 pmol/L (IQR: 47.8-184) in NSTEMI. DBRS (copeptin/hs-cTnI dual-negative biomarker rule-out strategy) had higher AUC than single biomarkers ( Conclusions: In Chinese patients, DBRS provided a safe and effective strategy for ruling out AMI. In addition, Combined negative results predicted safer 180-day post-discharge outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.